All In Biotech

Free tool

FAERS Monitor: Seasonale

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021544 or its brand name (Seasonale, Ethinyl Estradiol, Levonorgestrel). Reports on generic versions are filed under their own applications.

Reports

419

Serious

256

61% of reports

Hospitalization

103

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea39
  • vomiting30
  • drug ineffective28
  • headache22
  • fatigue19
  • pulmonary embolism19
  • abdominal pain16
  • dyspnoea16
  • cholecystitis chronic14
  • dizziness14
  • abdominal pain upper13
  • pruritus13
  • rash13
  • weight increased13
  • chest pain12

Reports by year received

View as table
YearReports
20053
200622
200715
20083
200917
201016
201168
201240
201310
201417
201528
201646
201715
201821
201918
202012
202114
202216
202310
20249
202512
20267

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,740 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
cholecystitis chronicSignal14105.262.81,340
pulmonary embolismSignal1910.06.5146
abdominal painSignal163.52.126
chest painSignal123.31.917
vomitingSignal303.22.344
abdominal pain upperSignal133.21.917
weight increasedSignal132.91.715
nauseaSignal392.51.834
headache221.81.27
pruritus131.71.03
rash131.50.92
dyspnoea161.40.92
dizziness141.40.81
fatigue191.20.81
drug ineffective281.10.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.